Nifty
Sensex
:
:
11426.75
38534.27
85.60 (0.75%)
319.80 (0.84%)

Pharmaceuticals & Drugs

Rating :
60/99  (View)

BSE: 524715 | NSE: SUNPHARMA

396.45
1.80 (0.46%)
15-Oct-2019 | 2:29PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  397.20
  •  400.00
  •  392.25
  •  394.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2271405
  •  9004.99
  •  616.80
  •  344.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 94,677.76
  • 31.08
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 97,916.52
  • 0.70%
  • 2.21

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.38%
  • 3.55%
  • 7.50%
  • FII
  • DII
  • Others
  • 0.88%
  • 17.05%
  • 16.64%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 21.91
  • 1.19
  • -2.45

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.50
  • -4.20
  • -8.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.04
  • -10.14
  • -27.35

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 34.53
  • 39.06
  • 34.53

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.46
  • 4.95
  • 3.36

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.96
  • 18.47
  • 15.48

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Net Sales
8,374.36
7,224.17
15.92%
7,163.92
6,977.10
2.68%
7,740.19
6,653.23
16.34%
6,937.63
6,650.34
4.32%
Expenses
6,446.13
5,617.47
14.75%
6,147.13
5,293.61
16.12%
5,587.30
5,199.85
7.45%
5,406.42
5,274.73
2.50%
EBITDA
1,928.23
1,606.70
20.01%
1,016.79
1,683.49
-39.60%
2,152.89
1,453.38
48.13%
1,531.21
1,375.61
11.31%
EBIDTM
23.03%
22.24%
14.19%
24.13%
27.81%
21.84%
22.07%
20.68%
Other Income
280.40
199.75
40.38%
281.53
302.75
-7.01%
193.06
129.19
49.44%
351.15
254.84
37.79%
Interest
104.06
130.90
-20.50%
150.03
155.38
-3.44%
144.79
95.33
51.88%
129.53
157.44
-17.73%
Depreciation
457.13
401.64
13.82%
454.05
455.24
-0.26%
471.05
339.32
38.82%
426.51
358.65
18.92%
PBT
1,647.44
1,273.91
29.32%
694.24
1,375.62
-49.53%
1,730.11
1,147.92
50.72%
111.94
1,114.36
-89.95%
Tax
146.06
163.86
-10.86%
-28.81
-176.69
-
270.92
792.52
-65.82%
218.91
111.40
96.51%
PAT
1,501.38
1,110.05
35.25%
723.05
1,552.31
-53.42%
1,459.19
355.40
310.58%
-106.97
1,002.96
-
PATM
17.93%
15.37%
10.09%
22.25%
18.85%
5.34%
-1.54%
15.08%
EPS
5.78
4.09
41.32%
2.65
5.46
-51.47%
5.18
1.34
286.57%
-0.91
3.80
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
30,216.10
29,065.91
26,415.54
31,308.14
28,108.61
27,392.01
16,080.36
11,299.86
8,019.49
5,727.90
4,007.45
Net Sales Growth
9.86%
10.03%
-15.63%
11.38%
2.62%
70.34%
42.31%
40.90%
40.01%
42.93%
 
Cost Of Goods Sold
8,219.93
7,868.97
7,318.73
8,164.20
6,170.19
6,732.84
2,777.68
2,076.36
1,647.61
1,460.40
1,098.45
Gross Profit
21,996.17
21,196.94
19,096.81
23,143.94
21,938.42
20,659.17
13,302.68
9,223.50
6,371.88
4,267.50
2,909.00
GP Margin
72.80%
72.93%
72.29%
73.92%
78.05%
75.42%
82.73%
81.62%
79.45%
74.50%
72.59%
Total Expenditure
23,586.98
22,792.27
20,880.73
21,625.92
19,950.29
19,615.54
9,120.95
6,437.76
4,836.43
3,785.07
2,644.63
Power & Fuel Cost
-
613.60
559.97
525.09
545.44
560.77
232.41
187.10
145.65
96.78
91.92
% Of Sales
-
2.11%
2.12%
1.68%
1.94%
2.05%
1.45%
1.66%
1.82%
1.69%
2.29%
Employee Cost
-
5,967.09
5,367.05
4,902.30
4,772.31
4,502.64
2,074.44
1,534.53
1,187.73
818.95
396.84
% Of Sales
-
20.53%
20.32%
15.66%
16.98%
16.44%
12.90%
13.58%
14.81%
14.30%
9.90%
Manufacturing Exp.
-
1,884.71
1,401.09
1,293.98
1,418.59
1,433.89
815.49
618.43
462.65
338.40
398.53
% Of Sales
-
6.48%
5.30%
4.13%
5.05%
5.23%
5.07%
5.47%
5.77%
5.91%
9.94%
General & Admin Exp.
-
2,729.20
3,288.76
3,113.67
2,956.85
2,894.97
978.48
793.38
629.48
480.66
215.47
% Of Sales
-
9.39%
12.45%
9.95%
10.52%
10.57%
6.08%
7.02%
7.85%
8.39%
5.38%
Selling & Distn. Exp.
-
2,621.13
1,864.55
2,520.64
2,262.35
2,236.40
1,394.78
763.01
516.55
372.14
290.33
% Of Sales
-
9.02%
7.06%
8.05%
8.05%
8.16%
8.67%
6.75%
6.44%
6.50%
7.24%
Miscellaneous Exp.
-
1,107.57
1,080.58
1,106.04
1,824.56
1,254.03
847.67
464.95
246.76
217.74
290.33
% Of Sales
-
3.81%
4.09%
3.53%
6.49%
4.58%
5.27%
4.11%
3.08%
3.80%
3.82%
EBITDA
6,629.12
6,273.64
5,534.81
9,682.22
8,158.32
7,776.47
6,959.41
4,862.10
3,183.06
1,942.83
1,362.82
EBITDA Margin
21.94%
21.58%
20.95%
30.93%
29.02%
28.39%
43.28%
43.03%
39.69%
33.92%
34.01%
Other Income
1,106.14
1,059.44
912.08
1,030.20
658.25
637.89
592.59
422.23
492.77
375.08
211.48
Interest
528.41
555.25
517.57
399.80
523.24
578.99
44.19
43.16
28.20
73.88
6.15
Depreciation
1,808.74
1,753.25
1,499.84
1,264.75
1,037.53
1,194.72
409.23
336.17
291.16
204.85
153.31
PBT
4,183.73
5,024.58
4,429.48
9,047.87
7,255.80
6,640.65
7,098.58
4,905.00
3,356.47
2,039.18
1,414.84
Tax
607.08
600.88
845.19
1,211.57
913.77
914.69
702.17
845.55
313.19
128.58
67.86
Tax Rate
14.51%
15.77%
24.29%
13.39%
13.91%
14.29%
15.33%
19.57%
9.33%
6.31%
4.80%
PAT
3,576.65
2,666.88
2,186.99
6,954.44
4,544.26
4,551.94
3,141.47
2,989.59
2,657.80
1,819.29
1,351.08
PAT before Minority Interest
3,053.60
3,209.32
2,633.79
7,836.30
5,656.86
5,488.21
3,879.00
3,475.87
3,043.28
1,910.60
1,346.98
Minority Interest
-523.05
-542.44
-446.80
-881.86
-1,112.60
-936.27
-737.53
-486.28
-385.48
-91.31
4.10
PAT Margin
11.84%
9.18%
8.28%
22.21%
16.17%
16.62%
19.54%
26.46%
33.14%
31.76%
33.71%
PAT Growth
-11.04%
21.94%
-68.55%
53.04%
-0.17%
44.90%
5.08%
12.48%
46.09%
34.65%
 
Unadjusted EPS
12.70
11.10
9.00
29.00
18.90
18.90
15.20
14.40
25.70
17.50
13.00

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
41,409.06
38,100.56
36,639.67
32,982.48
25,638.09
18,524.95
14,989.73
12,235.78
9,483.32
7,828.91
Share Capital
239.93
239.93
239.93
240.66
207.12
207.12
103.56
103.56
103.56
103.56
Total Reserves
41,169.13
37,860.63
36,397.10
32,736.26
25,374.38
18,317.83
14,886.17
12,132.22
9,379.76
7,725.35
Non-Current Liabilities
76.72
259.98
599.87
2,169.59
2,335.46
1,748.41
199.02
-225.23
-188.27
82.11
Secured Loans
109.47
217.69
185.59
7.73
40.69
43.76
41.90
49.65
4.38
100.35
Unsecured Loans
1,413.14
1,554.40
1,250.49
3,102.57
1,327.73
4.91
73.36
105.77
152.90
70.80
Long Term Provisions
430.39
404.46
1,211.11
1,895.86
2,532.34
2,601.62
787.06
138.73
13.00
0.00
Current Liabilities
17,339.62
19,864.32
17,887.02
13,143.96
16,146.81
5,989.59
2,841.25
2,618.49
1,730.88
757.92
Trade Payables
4,147.87
4,766.20
4,395.39
3,582.92
3,286.54
1,328.26
1,057.99
992.72
645.38
319.44
Other Current Liabilities
1,761.72
1,875.93
2,673.68
1,134.27
2,279.59
260.41
218.65
363.66
362.42
90.07
Short Term Borrowings
8,370.76
7,979.70
6,654.92
5,206.12
6,227.92
2,440.34
82.95
109.57
207.78
0.00
Short Term Provisions
3,059.27
5,242.49
4,163.03
3,220.65
4,352.76
1,960.58
1,481.66
1,152.54
515.30
348.41
Total Liabilities
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08
8,862.13
Net Block
21,836.54
18,852.65
17,675.17
15,872.25
12,682.47
6,817.28
5,647.47
3,951.35
3,293.35
1,938.82
Gross Block
31,687.04
26,948.81
24,466.42
22,180.41
20,406.89
10,485.12
8,709.22
6,448.66
5,319.27
2,740.07
Accumulated Depreciation
9,849.21
8,096.16
6,791.25
6,308.16
7,724.42
3,667.84
3,061.75
2,497.31
2,025.92
801.25
Non Current Assets
31,069.75
30,473.12
25,963.77
22,439.98
18,055.80
9,497.56
8,161.89
5,496.96
4,279.84
3,567.95
Capital Work in Progress
1,411.15
2,465.16
2,801.38
2,175.45
2,038.61
841.54
562.61
344.65
235.46
144.82
Non Current Investment
3,951.81
3,052.25
961.00
1,116.07
598.87
787.56
1,106.35
588.96
346.01
1,484.31
Long Term Loans & Adv.
3,848.29
6,052.97
3,844.04
2,322.87
2,631.91
1,016.98
802.56
593.29
377.27
0.00
Other Non Current Assets
21.96
50.09
682.18
953.34
103.94
34.20
42.90
18.71
27.75
0.00
Current Assets
31,069.19
31,635.90
32,953.65
29,941.30
28,915.75
18,686.46
11,503.03
10,293.37
7,593.05
5,294.18
Current Investments
3,950.72
4,090.62
230.88
713.81
2,117.43
1,998.46
1,305.22
1,623.91
1,883.75
1,682.07
Inventories
7,885.98
6,880.69
6,832.81
6,422.54
5,667.99
3,123.01
2,577.76
2,086.98
1,489.48
1,073.85
Sundry Debtors
8,884.20
7,815.28
7,202.61
6,775.66
5,106.13
2,200.42
2,412.23
2,078.74
1,104.87
1,174.77
Cash & Bank
7,275.60
9,929.38
15,140.84
13,181.65
10,998.04
7,590.15
4,058.71
3,367.19
2,204.63
508.89
Other Current Assets
3,072.69
891.31
718.25
530.51
5,026.16
3,774.42
1,149.11
1,136.55
910.32
854.60
Short Term Loans & Adv.
2,075.60
2,028.62
2,828.26
2,317.13
1,920.52
1,093.74
952.93
976.71
784.37
835.09
Net Current Assets
13,729.57
11,771.58
15,066.63
16,797.34
12,768.94
12,696.87
8,661.78
7,674.88
5,862.17
4,536.26
Total Assets
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08
8,862.13

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
2,196.45
3,907.15
7,082.21
6,685.86
5,615.74
3,959.20
3,356.58
2,234.46
2,283.10
781.13
PBT
3,810.20
3,478.98
9,047.87
6,570.63
6,402.90
4,581.17
4,314.89
3,355.36
2,035.95
1,414.84
Adjustment
1,968.66
1,382.22
500.67
1,856.92
773.61
-40.15
160.00
111.12
-171.18
-23.60
Changes in Working Capital
-2,696.00
-212.31
-409.21
246.77
179.59
207.10
-44.83
-1,005.25
487.65
-435.63
Cash after chg. in Working capital
3,082.86
4,648.89
9,139.33
8,674.32
7,356.10
4,748.12
4,430.06
2,461.23
2,352.42
955.61
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-886.41
-741.74
-2,057.12
-1,988.46
-1,740.36
-788.92
-1,073.48
-226.77
-69.32
-174.48
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-681.25
-3,370.81
-4,221.60
-4,371.59
-2,865.74
-2,366.76
-2,635.05
-862.71
-1,847.71
-213.74
Net Fixed Assets
-1,300.54
-714.76
-1,217.15
2,214.23
-4,631.67
-380.81
-341.28
-267.49
-212.50
-114.06
Net Investments
451.15
978.04
3,038.39
3,504.47
-18,860.43
-2,698.19
120.24
-836.36
450.27
-1,357.10
Others
168.14
-3,634.09
-6,042.84
-10,090.29
20,626.36
712.24
-2,414.01
241.14
-2,085.48
1,257.42
Cash from Financing Activity
-2,730.52
-1,539.26
-2,285.39
-1,888.53
-1,186.53
506.57
-664.99
-544.39
-804.19
-346.43
Net Cash Inflow / Outflow
-1,215.32
-1,002.92
575.22
425.74
1,563.47
2,099.01
56.54
827.36
-368.80
220.96
Opening Cash & Equivalents
7,906.45
8,642.36
8,031.69
7,183.49
4,358.70
2,069.11
1,752.67
810.49
633.87
451.24
Closing Cash & Equivalent
7,062.30
7,906.45
8,642.36
8,031.69
7,285.56
4,358.70
2,069.11
1,752.67
810.49
672.20

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
172.59
158.80
152.70
137.03
123.49
89.44
72.37
59.08
45.79
37.80
ROA
5.17%
4.35%
14.08%
11.39%
14.60%
16.21%
19.61%
22.00%
18.43%
15.91%
ROE
8.05%
7.05%
22.51%
19.32%
24.89%
23.15%
25.53%
28.02%
22.07%
18.11%
ROCE
8.68%
8.42%
21.48%
18.64%
25.06%
25.46%
31.39%
30.13%
23.60%
18.67%
Fixed Asset Turnover
1.92
1.03
1.35
1.34
1.79
1.70
1.51
1.38
1.44
1.57
Receivable days
54.10
103.47
80.78
76.12
48.20
51.72
71.46
71.49
71.57
91.85
Inventory Days
47.84
94.48
76.61
77.46
57.99
63.92
74.22
80.31
80.48
91.57
Payable days
77.81
92.31
77.57
75.24
52.05
56.33
65.15
64.51
51.06
42.23
Cash Conversion Cycle
24.13
105.64
79.82
78.34
54.14
59.31
80.53
87.29
100.98
141.19
Total Debt/Equity
0.25
0.27
0.27
0.26
0.35
0.14
0.02
0.03
0.04
0.02
Interest Cover
7.86
7.72
23.63
13.56
12.06
104.67
101.13
120.02
28.60
231.06

News Update


  • Sun Pharma launches CEQUA in US
    14th Oct 2019, 09:24 AM

    CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca

    Read More
  • Sun Pharma's arm presents study results that show significant skin clearance with ILUMYA
    10th Oct 2019, 09:16 AM

    The company has presented long-term follow-up data at the 28th EADV in Madrid

    Read More
  • Sun Pharma’s arm increases stake in PJSC Biosintez
    10th Sep 2019, 09:04 AM

    The total holding of wholly owned subsidiary company was increased from 96.96% to 100% in PJSC Biosintez

    Read More
  • Sun Pharma, CMS ink licensing agreement for generic products in Mainland China
    17th Aug 2019, 09:06 AM

    The initial term of the agreement shall be 20 years from the first commercial sale of the respective products in Mainland China

    Read More
  • Sun Pharma enters into licensing agreement with CSIR-IICT
    14th Aug 2019, 14:27 PM

    Under the terms of the license agreement, the company gets exclusive global license for the said patents and any other future patents covered in the agreement

    Read More
  • Sun Pharma reports 31% rise in Q1 consolidated net profit
    13th Aug 2019, 16:08 PM

    Total consolidated income of the company increased by 15.67% at Rs 8,587.38 crore for Q1FY20

    Read More
  • Sun Pharma Inds. - Quarterly Results
    13th Aug 2019, 15:06 PM

    Read More
  • Sun Pharma discontinues operations at two clinical pharmacology units in Vadodara
    3rd Aug 2019, 15:38 PM

    The company is discontinuing operations to bring in efficiencies in cost and processes

    Read More
  • Sun Pharma aims 'low-to-mid teens' growth in consolidated revenues in FY20
    1st Aug 2019, 10:18 AM

    The company is focused at growing each of its business verticals faster than the market in which it operates

    Read More
  • Sun Pharma files application for Tildrakizumab in Japan
    1st Aug 2019, 09:13 AM

    The recent acquisition of Pola Pharma in Japan will help the company leverage Pola’s strong presence

    Read More
  • Sun Pharma launches Ezallor Sprinkle capsules in US
    15th Jul 2019, 08:54 AM

    Ezallor Sprinkle capsules is used for the treatment of three types of elevated lipid disorders in people

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.